Part 3 of our Deep GUNA Research series, for practitioners.
This article is written for a practitioner audience and draws directly on GUNA's own published research. It is educational in nature and does not replace clinical judgement or personalised medical advice.
The primary group of INET medicines carries the letter F for female patients and M for male patients next to the brand name: K2F and K2M. These are the basic INET medicines, and every secondary and tertiary product in the range — covered later in this series — is built on the same underlying structure.
Full Composition
K2F and K2M contain suis organotherapics of the neuroendocrine axis in decimal dilutions D6/D12/D30/D200.
The one deliberate addition to this glandular sequence is Melatonin, combined specifically with Glandula pinealis suis. GUNA chose this pairing to strengthen neuroendocrine activity and obtain the optimum therapeutic effect — pairing the pineal gland's own tissue with the hormone it is best known for producing. Their tropism is clearly glandular, and their action can be described as "re-starting" neuroendocrine functionality.
Posology
10 drops, 2-3 times a day. Do not exceed the maximum daily dose of 30 drops.
Why the Composition Follows the Axis So Closely
This structure mirrors the neuroendocrine-immune chain covered in the first article of this series almost gland for gland: cerebrum, pineal gland, hypophysis, thyroid, thymus, pancreas, the gonads, and the adrenal glands — each one a checkpoint in the interconnected chain linking the central nervous system to the endocrine and immune networks. Where a chronic pathology has caused deregulation of neuroendocrine homeostasis at the receptor level, K2F and K2M are designed to work through that entire chain at once, rather than targeting a single gland in isolation.
This is also why K2F and K2M are described as the primary group — the foundational layer that Senectus F/M and K2F-DIA/K2M-DIA, covered in the next two articles, are built on top of. Where those later groups add single homeopathic remedies, vitamins or diabetes-specific adjuncts for more particular presentations, K2F and K2M represent the basic, broad-spectrum starting point: restoring the functional integrity of the axis itself.
Clinical Scope
Because K2F and K2M work across the whole neuroendocrine axis rather than a single organ, GUNA's clinical experience with the two products spans an unusually wide range of chronic, degenerative presentations — from functional disorders of the menstrual cycle and climacteric syndrome, to degenerative arthropathy and osteoporosis, to andropause and anxious-depressive syndrome in the elderly. The full indications list for INET as a whole is covered in the previous article in this series.
The next article looks at Senectus F and Senectus M — the secondary group of INET medicines, and the full rationale behind everything GUNA added to the basic K2F/K2M structure for the physiology of ageing.
Featured products
Explore the full Guna Endocrinology range — INET compounds and neuroendocrine support built on GUNA’s PNEI research.
Not sure which remedy is right for you?
Try our Natural Remedy Finder, or contact our team for guidance.
Related reading
- INET Pharmacology: The Two Therapeutic Methods and Full Clinical Indications
- Senectus F and Senectus M in Full: Composition and Ingredient Rationale
- GUNA's Clinical Case Reports: Male Infertility and Type 1 Diabetes
Source: GUNA, *From Homotoxicology to INET*, "The Primary Group of Medicines."
Tags: Deep Guna Research, Guna Articles, K2F, K2M, Neuroendocrine Axis